详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Ursolic Acid Alleviates Cancer Cachexia and Prevents Muscle Wasting via Activating SIRT1

90| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Department of Oncology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China [2]Reproductive Medicine Center, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China [3]Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China

出处：

DOI：

ISSN：

关键词： ursolic acid cancer cachexia skeletal muscle SIRT1 Ex-527 NF-kappa B

摘要：

Skeletal muscle wasting is the most remarkable phenotypic feature of cancer cachexia that increases the risk of morbidity and mortality. However, there are currently no effective drugs against cancer cachexia. Ursolic acid (UA) is a lipophilic pentacyclic triterpene that has been reported to alleviate muscle atrophy and reduce muscle decomposition in some disease models. This study aimed to explore the role and mechanisms of UA treatment in cancer cachexia. We found that UA attenuated Lewis lung carcinoma (LLC)-conditioned medium-induced C2C12 myotube atrophy and muscle wasting of LLC tumor-bearing mice. Moreover, UA dose-dependently activated SIRT1 and downregulated MuRF1 and Atrogin-1. Molecular docking results revealed a good binding effect on UA and SIRT1 protein. UA rescued vital features wasting without impacting tumor growth, suppressed the elevated spleen weight, and downregulated serum concentrations of inflammatory cytokines in vivo. The above phenomena can be attenuated by Ex-527, an inhibitor of SIRT1. Furthermore, UA remained protective against cancer cachexia in the advanced stage of tumor growth. The results revealed that UA exerts an anti-cachexia effect via activating SIRT1, thereby downregulating the phosphorylation levels of NF-?B and STAT3. UA might be a potential drug against cancer cachexia.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区

医学

小类 | 2 区肿瘤学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

JCR分区：

出版当年[2021]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

影响因子： 4.5 最新[2023版] 4.9 最新五年平均 6.575 出版当年[2021版] 6.886 出版当年五年平均 6.639 出版前一年[2020版] 5.2 出版后一年[2022版]

第一作者：

第一作者单位： [1]Department of Oncology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Pharmacological Inhibition of HMGB1 Prevents Muscle Wasting [2]Ursolic acid promotes robust tolerance to cardiac allografts in mice [3]Protective Effects of Dioscin Against Doxorubicin-Induced Hepatotoxicity Via Regulation of Sirt1/FOXO1/NF-kappa b Signal [4]The SIRT1 inhibitor EX-527 suppresses mTOR activation and alleviates acute lung injury in mice with endotoxiemia [5]Protein therapy of skeletal muscle atrophy and mechanism by angiogenic factor AGGF1 [6]Coix seed oil ameliorates cancer cachexia by counteracting muscle loss and fat lipolysis [7]Preclinical Investigation of Alpinetin in the Treatment of Cancer-Induced Cachexia via Activating PPARγ [8]Inhibitory effects of SRT1720 on the apoptosis of rabbit chondrocytes by activating SIRT1 via p53/bax and NF-kappa B/PGC-1 alpha pathways [9]NKILA inhibits NF-kappa B signaling and suppresses tumor metastasis [10]NF-kappa B Downregulates Cbl-b through Binding and Suppressing Cbl-b Promoter in T Cell Activation